BUSINESS BRIEFING / DRUGS
- Share via
Bristol-Myers Squibb Co. said it agreed to buy Medarex Inc. for about $2.4 billion as a way to double its pipeline of experimental biological drugs, including one nearing U.S. approval for skin cancer.
The New York-based firm is acquiring companies and forming partnerships to find products to offset losses from Plavix, its top seller, when the cholesterol drug faces generic competition beginning in 2012.
The deal gives Bristol-Myers full ownership of skin cancer drug ipilimumab, which it had been developing with Princeton, N.J.-based Medarex.
Ipilimumab, an experimental drug for metastatic melanoma, is in the third and final stage of testing typically required for Food and Drug Administration approval. The drug is also being studied in lung and prostate cancers.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
